Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

Nigeria faces unique challenges in addressing the potential threat posed by HMPV. These include limited diagnostic capacity, ...

A 4-year-old boy from Ahmedabad city has contracted human metapneumovirus, taking the number of HMPV cases in Gujarat to ...

An Ahmedabad boy, aged four, has tested positive for human metapneumovirus, raising Gujarat's total cases to eight. The child ...

A 4-year-old boy in Ahmedabad has been diagnosed with human metapneumovirus, increasing Gujarat's cases to eight. The child is in stable condition. The virus, spreading since 2001, resembles the ...

The child is currently being treated at a trust-run hospital and his condition is stable, a medical officer said ...

SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs such ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

• Respiratory syncytial virus (RSV) infections are above the alert level. • Seasonal influenza (flu) infections are well ...

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...